Lonza has announced that its CEO, Wolfgang Wienand, will present at the Jefferies Global Healthcare Conference in London on 18 November 2026. The presentation and subsequent question-and-answer session are scheduled from 15:30 to 15:55 GMT (16:30 to 16:55 CET). The announcement, made via NEWMEDIAWIRE, signals the company's continued engagement with the investment community at a major healthcare sector event.
The timing of the presentation is significant for investors and analysts tracking Lonza's performance and strategic direction. As the world's leading contract development and manufacturing organization (CDMO), Lonza plays a critical role in the healthcare industry, partnering with pharma and biotech companies to turn breakthrough innovations into viable therapies. With approximately 17,000 colleagues across three continents, the company generated sales of CHF 3.4 billion and a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Wienand's remarks at the Jefferies conference will likely provide insight into how Lonza intends to sustain this momentum amid evolving market conditions.
For those unable to attend in person, the session will be webcast live, and a replay will be available on the Lonza Investor Relations website for 90 days. The live audio webcast can be accessed via this link. This broad accessibility ensures that a wide range of stakeholders can hear directly from Lonza's leadership, which is particularly important given the company's role in the healthcare supply chain.
The Jefferies Global Healthcare Conference brings together industry leaders, investors, and analysts, making it a key forum for companies to communicate their vision and results. Lonza's participation underscores its commitment to transparency and investor engagement. As a company listed on the SIX Swiss Exchange with a secondary listing on the Singapore Exchange Securities Trading Limited, Lonza operates under rigorous disclosure requirements, and presentations at such conferences are closely watched for signals about future growth and operational priorities.
Wienand's presentation comes at a time when the CDMO sector is under scrutiny for its ability to scale innovation and meet global demand for therapies. Lonza's recent financial results demonstrate robust performance, but the conference provides an opportunity to address questions about capacity expansion, technological investments, and strategic partnerships. Investors will be listening for updates on how Lonza plans to leverage its cutting-edge science, smart technology, and lean manufacturing to maintain its competitive edge.
For more information about Lonza, visit www.lonza.com. The original release can be viewed on www.newmediawire.com.
